CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $3.54B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.54: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.54BUSDvs all stocks (USD)
Trailing P/E
37.98xvs Medical Devices peers
Revenue (TTM)
1.33BUSDvs all stocks (USD)
Profit Margin
7.29%vs Medical Devices peers
Beta
0.5210xvs all stocks
52-Week Change
5.54%vs all stocks
Market Capitalization
3.54BUSDvs all stocks (USD)
Enterprise Value
4.57BUSDvs all stocks (USD)
Trailing P/E
37.98xvs Medical Devices peers
Forward P/E
13.84xvs Medical Devices peers
PEG Ratio
-0.2773xvs Medical Devices peers
Price to Sales (TTM)
2.65xvs Medical Devices peers
Price to Book (MRQ)
4.42xvs Medical Devices peers
Enterprise to Revenue
3.42xvs Medical Devices peers
Enterprise to EBITDA
12.79xvs Medical Devices peers
Gross Margin
57.23%vs Medical Devices peers
Profit Margin
7.29%vs Medical Devices peers
Operating Margin
13.88%vs Medical Devices peers
Return on Assets (TTM)
6.49%vs Medical Devices peers
Return on Equity (TTM)
12.03%vs Medical Devices peers
Revenue (TTM)
1.33BUSDvs all stocks (USD)
Revenue per Share (TTM)
28.28USDUpdated Jul 19, 2026Quarterly Revenue Growth
4.80%vs Medical Devices peers
Gross Profit (TTM)
792.87MUSDvs all stocks (USD)
EBITDA (TTM)
353.12MUSDvs all stocks (USD)
Net Income (TTM)
97.31MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.76%vs Medical Devices peers
Operating Cash Flow (TTM)
293.22MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
298.09MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.33BUSDFY2026 · Mar 31, 2026Cost of Goods Sold
546.44MUSDFY2026 · Mar 31, 2026Gross Profit
787.59MUSDFY2026 · Mar 31, 2026Operating Income
241.40MUSDvs all stocks (USD)
Pre-tax Income
128.03MUSDFY2026 · Mar 31, 2026Income Tax Expense
30.72MUSDFY2026 · Mar 31, 2026Net Income
97.31MUSDFY2026 · Mar 31, 2026EBIT
156.73MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
353.12MUSDFY2026 · Mar 31, 2026Research & Development
59.77MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
442.42MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
28.70MUSDFY2026 · Mar 31, 2026EPS (Basic)
2.06USDFY2026 · Mar 31, 2026EPS (Diluted)
2.05USDFY2026 · Mar 31, 2026Basic Shares Outstanding
47.18MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
47.18MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
97.31MUSDFY2026 · Mar 31, 2026Operating Cash Flow
254.25MUSDFY2026 · Mar 31, 2026Free Cash Flow
252.88MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
245.44MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
97.31MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
111.72MUSDFY2026 · Mar 31, 2026Deferred Taxes (CF)
-714.00KUSDFY2026 · Mar 31, 2026Stock-based Compensation
33.83MUSDFY2026 · Mar 31, 2026Other Non-cash Items
3.94MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-14.88MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
23.06MUSDFY2026 · Mar 31, 2026Capital Expenditures
1.38MUSDFY2026 · Mar 31, 2026Net Acquisitions
-60.18MUSDFY2026 · Mar 31, 2026Other Investing Activity
-51.89MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
-110.70MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
300.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-306.25MUSDFY2026 · Mar 31, 2026Common Stock Repurchase
-175.00MUSDFY2026 · Mar 31, 2026Other Financing Charges
-102.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
-181.35MUSDFY2026 · Mar 31, 2026Shares Outstanding
45.25MSharesUpdated Jul 19, 2026Float Shares
44.86MSharesUpdated Jul 19, 2026Shares Short
2.91MSharesUpdated Jul 19, 2026Short Ratio
2.83daysvs all stocks
Short % of Shares Outstanding
8.70%vs all stocks
% Held by Insiders
1.22%vs all stocks
% Held by Institutions
109.50%vs all stocks
Total Cash (MRQ)
246.26MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.42USDUpdated Jul 19, 2026Total Debt (MRQ)
1.27BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.60xvs Medical Devices peers
Current Ratio (MRQ)
2.95xvs Medical Devices peers
Book Value per Share (MRQ)
17.60USDUpdated Jul 19, 2026Total Assets
2.40BUSDvs all stocks (USD)
Total Current Assets
834.88MUSDFY2026 · Mar 31, 2026Total Liabilities
1.60BUSDFY2026 · Mar 31, 2026Total Non-current Assets
1.56BUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
1.32BUSDFY2026 · Mar 31, 2026Total Current Liabilities
282.60MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
245.44MUSDFY2026 · Mar 31, 2026Accounts Receivable
216.85MUSDFY2026 · Mar 31, 2026Inventory
306.37MUSDFY2026 · Mar 31, 2026Accounts Payable
51.06MUSDFY2026 · Mar 31, 2026Short-term Debt
5.01MUSDFY2026 · Mar 31, 2026Deferred Revenue
42.31MUSDFY2026 · Mar 31, 2026Other Current Liabilities
116.03MUSDFY2026 · Mar 31, 2026Long-term Debt
1.22BUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
59.39MUSDFY2026 · Mar 31, 2026Common Stock (Book)
453.00KUSDFY2026 · Mar 31, 2026Retained Earnings
279.34MUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
796.32MUSDvs all stocks (USD)
52-Week Low
47.32USDUpdated Jul 19, 202652-Week High
87.32USDUpdated Jul 19, 202652-Week Change
5.54%vs all stocks
Beta
0.5210xvs all stocks
50-Day MA
69.41USDUpdated Jul 19, 2026200-Day MA
66.07USDUpdated Jul 19, 2026Avg 10-Day Volume
588.62KSharesUpdated Jul 19, 2026Avg 30-Day Volume
901.97KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
2.05USDUpdated Jul 19, 2026Other Income / Expense
-84.67MUSDFY2026 · Mar 31, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.07
Financial Health
Altman Z-Score 2.54: grey zoneSignificant
Altman Z-Score: 2.54
High earnings qualityNotable
Earnings Quality Score: 1.10
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $3.54B, above the global median of $1.15BNotable
Market cap (USD): 3,538,424,236Global Median: 1,146,734,693.424
Revenue is $1.33B, above the global median of $520.53MNotable
Revenue (USD): 1,334,027,008Global Median: 520,528,949.311
Levered free cash flow is $298.09M, above the global median of $16.24MNotable
Levered free cash flow (USD): 298,094,240Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Pegbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Organon & Co.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arcutis Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Laboratorios Farmacéuticos Rovi SA
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alumis Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Ideaya Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
IIFL Finance Ltd.
1 interpretationFCF Ratios Elevated
SGS SA
1 interpretationFCF Ratios Elevated
Harmony Biosciences Holdings, Inc.
1 interpretationFCF Ratios Elevated